team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference.
Among people with secondary progressive multiple sclerosis (SPMS) without active disease, high blood levels of the proteins neurofilament light chain, known as NfL, and glial fibrillary acidic protein, or GFAP, are associated with an increased risk of worsening disability, new research shows.
Measuring levels of certain proteins in the blood can provide important information about a person’s health. NfL is released into the blood when neurons or nerve cells are damaged or destroyed. As such, levels of NfL in the blood are indicative of injury in the nervous system. GFAP, meanwhile, is associated with the activity of star-shaped neural support cells called astrocytes, and also is a marker of nervous system injury.
(0)
Xywav demonstrated statistically significant differences in change in Epworth Sleepiness Scale score (p-value
The safety profile in this study was consistent with the known safety profile of Xywav with no new safety signals observed in this population
Company to host investor webcast today at 12:30 p.m. ET
DUBLIN, April 20, 2021 /PRNewswire/
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced positive results from the Phase 3 study of Xywav
TM (calcium, magnesium, potassium, and sodium oxybates) oral solution in adult patients with idiopathic hypersomnia, which will be presented during the Clinical Trials Plenary Session of the 2021 American Academy of Neurology (AAN) Annual Meeting between 10:00 a.m. and 12:30 p.m. ET. Jazz will host an investor and analyst presentation via webcast today at 12:30 p.m. ET.
team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference.
Common B-cell depleting therapies, such as rituximab and Ocrevus (ocrelizumab), may result in shorter duration B-cell depleting effects in African American patients with multiple sclerosis (MS) or neuromyelitis optica spectrum disorder (NMOSD) than in white patients, a study suggests.
“While previous research has shown that this type of [into-the-vein] therapy is effective for people with those diseases, we also know that Black people tend to have more severe courses of MS,” llya Kister, MD, said in a press release. Kister, of the NYU Grossman School of Medicine in New York, is the study’s senior author and a fellow of the American Academy of Neurology.
Study reveals your neighbourhood may affect your brain health ANI | Updated: Apr 20, 2021 15:22 IST
Washington [US], April 20 (ANI): Middle-aged and older people living in more disadvantaged neighbourhoods areas with higher poverty levels and fewer educational and employment opportunities had more brain shrinkage on brain scans and showed a faster decline on cognitive tests than people living in neighbourhoods with fewer disadvantages, according to a new study.
The study published in the online issue of Neurology, the medical journal of the American Academy of Neurology. Researchers say such brain ageing may be a sign of the earliest stages of dementia. Worldwide, dementia is a major cause of illness and a devastating diagnosis, said study author Amy J. H. Kind M.D., PhD, of the University of Wisconsin School of Medicine and Public Health in Madison.
MS Treatment Wears Off More Quickly in Black Patients By Deborah Brauser
April 19, 2021 – Black patients with the autoimmune diseases multiple sclerosis (MS) or neuromyelitis optica spectrum disorder (NMOSD) may respond differently to a common MS treatment compared to their white peers, new research suggests.
White blood cells called B-cells are involved in the autoimmune response that damages the nervous system in people with MS and NMOSD. One common type of therapy, given as an infusion, targets a protein on B-cells called CD20 to kill the cells and stop them from playing their role in nerve degeneration.
In a new study of almost 200 patients, researchers found that B-cells came back sooner in Black participants with MS or NMOSD 6 to 12 months after they received anti-CD20 infusion therapy with rituximab or ocrelizumab, compared to white participants.